Unknown

Dataset Information

0

Atomic basis for the species-specific inhibition of ?V integrins by monoclonal antibody 17E6 is revealed by the crystal structure of ?V?3 ectodomain-17E6 Fab complex.


ABSTRACT: The function-blocking, non-RGD-containing, and primate-specific mouse monoclonal antibody 17E6 binds the ?V subfamily of integrins. 17E6 is currently in phase II clinical trials for treating cancer. To elucidate the structural basis of recognition and the molecular mechanism of inhibition, we crystallized ?V?3 ectodomain in complex with the Fab fragment of 17E6. Protein crystals grew in presence of the activating cation Mn(2+). The integrin in the complex and in solution assumed the genuflected conformation. 17E6 Fab bound exclusively to the Propeller domain of the ?V subunit. At the core of ?V-Fab interface were interactions involving Propeller residues Lys-203 and Gln-145, with the latter accounting for primate specificity. The Propeller residue Asp-150, which normally coordinates Arg of the ligand Arg-Gly-Asp motif, formed contacts with Arg-54 of the Fab that were expected to reduce soluble FN10 binding to cellular ?V?3 complexed with 17E6. This was confirmed in direct binding studies, suggesting that 17E6 is an allosteric inhibitor of ?V integrins.

SUBMITTER: Mahalingam B 

PROVIDER: S-EPMC4022854 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Atomic basis for the species-specific inhibition of αV integrins by monoclonal antibody 17E6 is revealed by the crystal structure of αVβ3 ectodomain-17E6 Fab complex.

Mahalingam Bhuvaneshwari B   Van Agthoven Johannes F JF   Xiong Jian-Ping JP   Alonso José Luis JL   Adair Brian D BD   Rui Xianliang X   Anand Saurabh S   Mehrbod Mehrdad M   Mofrad Mohammad R K MR   Burger Christa C   Goodman Simon L SL   Arnaout M Amin MA  

The Journal of biological chemistry 20140401 20


The function-blocking, non-RGD-containing, and primate-specific mouse monoclonal antibody 17E6 binds the αV subfamily of integrins. 17E6 is currently in phase II clinical trials for treating cancer. To elucidate the structural basis of recognition and the molecular mechanism of inhibition, we crystallized αVβ3 ectodomain in complex with the Fab fragment of 17E6. Protein crystals grew in presence of the activating cation Mn(2+). The integrin in the complex and in solution assumed the genuflected  ...[more]

Similar Datasets

| S-EPMC2374077 | biostudies-literature
| S-EPMC3526572 | biostudies-literature
| S-EPMC1171204 | biostudies-other
| S-EPMC3317794 | biostudies-literature
| S-EPMC103727 | biostudies-literature
| S-EPMC1567891 | biostudies-literature
| S-EPMC5916558 | biostudies-literature
| S-EPMC4108548 | biostudies-literature
| S-EPMC102577 | biostudies-literature
| S-EPMC7170532 | biostudies-literature